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Abstract
Neurodegeneration leads to the loss of normal anatomy and physiology of the neuronal system
in a human body. The hallmark of most neurodegenerative diseases is abnormal folding and
accumulation of proteins within neuronal cell bodies that is not present in healthy people. These
changes in normal protein metabolism often lead to neuronal cell death and failure of the affected
regions of the central nervous system. Abnormal protein accumulation may be attributed to
dysfunctional mitochondria and damage by reactive oxygen species. In addition to causing altered
protein accumulation, dysfunctional mitochondria and an excess of reactive oxygen species also lead to
errors in glucose metabolism, which create problems in energy production and insulin signaling. The
problems in these processes are targets for therapeutic techniques to find treatments for
neurodegeneration and include insulin sensitizing compounds, and antioxidants. No treatments have yet
been found successful to rid a person of neurodegeneration completely; however, progress has been
made towards targeting the mitochondria and reactive oxygen species to halt the progress of
neurodegenerative diseases in humans.
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Introduction
Neurodegenerative diseases cause death of neuronal cells to the point of progressive
pathological disease. How these neurons die is still a question in deep study, although many
breakthrough findings have been made. There are many different types of neurodegenerative diseases
including but not limited to Alzheimer's disease, Parkinson's disease, Huntington's disease, and
Amyotrophic Lateral Sclerosis (ALS). These diseases affect millions of people worldwide (Cai et al.,
2012). As the two most prevalent of all neurodegenerative diseases in the United States, Alzheimer's
disease affected 5.4 million people and Parkinson's disease affected 1.5 million people on average last
year. Huntington's disease is rarer, with 30,000 people in the United States showing symptoms of it last
year (Pal, 2012). However, since the average life expectancy of the population is rising, and
neurodegenerative disease diagnoses increase with age, the number of neurodegenerative cases has also
been rising with the elderly population (Forman et al., 2004).
Alzheimer's disease is characterized by plaques made of amyloid beta protein and
neurofibrillary tangles of overly-phosphorylated tau protein. These plaques cause clinical symptoms
including dementia, or cognitive decline. In Parkinson's disease, there is a loss of neurons in the
substantia nigra, with inclusions called Lewy bodies that are accumulated α-synuclein and ubiquitin
proteins. The loss of these motor neurons causes rigidity and tremors in the human body suffering from
Parkinson's. Huntington's disease is characterized by a “loss of long projection neurons in the cortex
and striatum” (Lin & Beal, 2006). There is also an irregular polyglutamine addition in the N terminal of
the huntingtin protein in this disease (Charvin et al., 2005). A person with Huntington's disease
develops signs of psychiatric problems and dementia from these physiological problems developing in
the brain. Amyotrophic Lateral Sclerosis is known for the degeneration of motor neurons in the cortex,
3

MITOCHONDRIAL DYSFUNCTION AND REACTIVE OXYGEN SPECIES IN
NEURODEGENERATION
brain stem, and spinal cord along with accumulations of mutated copper and zinc superoxide
dismutase. Somebody with ALS will show progressive weakness and atrophy (Lin & Beal, 2006). All
of these diseases act in different ways to affect the body, but it is believed that they all are initiated in
similar ways.
There are reasons to believe that the mitochondria play a role in the degeneration of neurons in
these diseases. The mitochondria play a big role in how all cells function properly. Mitochondria
contain its own DNA (mtDNA), and run many of the human body's energy metabolic systems like the
Krebs cycle (also known as the citric acid cycle) and the electron transport chain to make adenosine
triphosphate (ATP). This ATP lets the body function by providing energy to our cells, tissues, and
organs. The circular mtDNA accumulates many mutations as a person ages (Linnane et al., 1989; Vieira
& Kroemer, 1999). These mutations may lead to mitochondrial dysfunction and is hypothesized to
cause serious trouble in the human body including the initiation and progression of neurodegenerative
diseases.
Reactive oxygen species (ROS) are known to accelerate aging and to cause damage to many
cells in the body, including neurons. When the body metabolizes oxygen in oxidative phosphorylation,
mitochondria create reactive oxygen species. Reactive oxygen species are molecules with an unpaired
electron and as a result, are very reactive and damaging to our cells (Halliwell, 1992). These molecules
are “redox reactive” and are able to affect different cell components in many ways. For example, ROS
are able to oxidize proteins, which could negatively affect active sites on enzymes, not allowing the
substrate to properly bind. ROS could change the shape of proteins completely, which would also have
an effect on how the protein functions. These molecules can also cause peroxidation of lipids, which
causes degradation of fatty acids and lipids. These components make up the plasma membranes and
organelle membranes of the cells. Once lipid peroxidation takes place these membranes are likely to
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become seriously damaged. This could cause detrimental effects to the cell for the plasma membrane
protects the cell from many potential dangers. ROS also directly oxidize DNA and cause mutations in
some cases (Andersen, 2004). This is why the reactive oxygen species have been closely linked to
neurodegeneration.
The mitochondria and reactive oxygen species together can lead to problems such as a faulty
glucose metabolism and decreased ATP. Several steps in these important metabolic processes are
targets for therapeutic intervention to treat neurodegenerative disorders. In order to understand
neurodegenerative disorders effectively, it is important to recognize that there may be multiple
etiologies and several different complex pathways that lead to the progression of the various forms of
these ailments.
Mitochondrial Dysfunction and Neurodegenerative Diseases
The mitochondria are the most important and essential organelles for energy production and
cellular metabolism. The mitochondria are critical energy conservation centers in human cells. Through
oxidative phosphorylation they create ATP with the food that humans eat and the oxygen that humans
breathe (Rego & Oliveira, 2003). ATP is the energy currency that every cell needs in order to carry out
processes that are needed to allow an organism to survive. Some cells, like muscle cells, can survive
without a lot of mitochondria, because they can survive on the “glycolytic oxidation of stored glucose
molecules” (Fiskum et al., 1998), however, this is not the case with neurons. Neurons need the
mitochondria to be fully functional because they are highly metabolically active and do not have a
backup system as some other cells do for energy production. (Fiskum et al.,1998).
When mitochondria in neurons do become dysfunctional, many problems can occur. One way
the mitochondria become damaged and dysfunctional is through ROS. ROS cause a decrease in the
functionality of many needed mitochondrial enzymes. These enzymes include pyruvate dehydrogenase
5
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and cytochrome oxidase. The cell counts on these enzymes for both the Krebs cycle and glucose
metabolism and once deficient in these enzymes, the mitochondria become dysfunctional (Colca &
Feinstein, 2012). The stress associated with enzyme malfunctions in metabolic pathways may also
account for some mutagenesis in the mitochondrial DNA. Another way mitochondria are proposed to
become dysfunctional is through mutations accumulated over a person's lifetime. The mtDNA is known
for “large scale deletions or point mutations” that cause adverse effects to the mitochondria function by
negatively affecting energy production processes (Lin & Beal, 2006).
Once some of the mitochondria are not working, less ATP are produced because oxidative
phosphorylation becomes less prevalent in a given cell. With less ATP, fewer processes in the cell take
place. These processes include autophagy and lysosomal degradation. Unfortunately, these processes
are necessary for getting rid of proteins that are folded improperly and for getting rid of many other
waste products in the cell. When the mitochondria do not make enough ATP to perform these processes,
the cell cannot dispose or recycle these deformed proteins and they accumulate and aggregate.
In addition, if the cell no longer has enough ATP, it cannot perform normal cell-to-cell
communication via the synapses (Reddy et al., 2011; Colca & Feinstein, 2012). This is an important
function for the nervous system because it keeps the brain in communication with the rest of the body
and the external environment. This loss of critical information exchange by the central nervous system
leads to the visible signs and progressive pathology of neurodegenerative disease (MENA report,
2013).
The mitochondria in a cell are also known for keeping calcium levels stable, as an excess in
calcium can lead to cell death. (Castellani et al., 2002) This means that dysfunction in the mitochondria
is able to cause spikes in calcium levels, for it no longer has sufficient ATP to maintain membrane
potential to keep the cells in a state of homeostasis. (Rego & Oliveira, 2003). When calcium levels
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fluctuate in the cell, apoptosis is usually initiated because more calcium creates increased sensitivity to
“apoptotic stimuli” (Rizzuto et al., 2003). These apoptotic stimuli include the Bax and Bcl proteins,
which activate the opening of the mitochondrial permeability transition pore and eventually this leads
to cell death.
Studies have shown that with dysfunctional mitochondria comes an increase in reactive oxygen
species that are produced in the mitochondria. This may be due to an alteration in the electron transport
chain which causes defects in the enzymatic complexes, resulting in the release of an excess of ROS
(Benzi & Moretti, 1995). Reactive oxygen species endanger the neuron by causing damage to
membranes, proteins, and nucleic acids. Not only do reactive oxygen species cause more damage to the
mitochondria, but they also initiate apoptosis, programmed death of the cell. Apoptosis is a very orderly
process in the cell, and it happens only in extreme cases when the cell knows it cannot be repaired.
When mitochondria go through dysfunctional changes, there is a very good chance the cell will go
through apoptosis. One trigger of apoptosis is through the opening of the mitochondrial permeability
transition pore (MPT) on the inner membrane of the mitochondria (Castellani et al., 2002; Vieira &
Kroemer, 1999). The MPT is activated during a decrease in mitochondrial function characterized by an
increase in reactive oxygen species, a decrease in ATP production, and an associated rise in calcium.
The opening of this pore induces the release of the cytochrome c protein which activates caspases
(Castellani et al., 2002) causing apoptosis (Colca & Feinstein, 2012). The sensitivity of the
mitochondrial permeability transition pore to increased calcium has been shown to be increased by
oxidative stress. Therefore dysfunctional mitochondria with increased ROS are creating an opportune
environment for apoptosis through the opening of the MPT pore (Pastrushev et al., 2004). Figure 1
depicts some ways that neurons go through cell death with details of apoptosis and other pathways that
lead to cell death.
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Figure 1- (Mattson, 2000)
As seen by all of these examples, any form of mitochondrial dysfunction is very harmful to the
neurons in the brain and it leads to neurodegeneration. It elicits the process of protein accumulation and
aggregation in many ways. There have been studies done that show that protein accumulation can also
arise inside the mitochondria. A good example of this would be the amyloid precursor protein in
Alzheimer's disease. This protein has been shown to accumulate inside the protein channels of the
mitochondria, causing damage to the mitochondria (Devi et al., 2006). There have been similar findings
with an array of proteins in various neurodegenerative diseases, showing that protein accumulation
inside the mitochondria leads to dysfunction and further destruction of neurons (Kwong et al., 2006;
Cho et al., 2010; Colca & Feinstein, 2012). Figure 2 below shows how accumulation of different
pathogenic proteins like the α-synuclein protein and the parkin protein affect mitochondria.
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Figure 2- (Knott et al., 2008)
It is unknown as to whether the dysfunctional mitochondria cause the protein aggregation and
accumulation, or if the protein aggregation causes the mitochondria to become dysfunctional. There
have been clues and evidence to support each claim but it is believed that the combination of both
advances neurodegeneration.
Oxidative Stress and Neurodegenerative Diseases
Reactive oxygen species and reactive nitrogen species cause unfavorable effects to all cells in
the body, especially the neurons in the brain (Multhaup et al., 1997). The brain does not regenerate as
other parts of the body do, and it is very active metabolically, therefore very susceptible to injury by
oxidative stress (Andersen, 2004). Many of the reactive oxygen species are made in the mitochondria.
These species usually include “hydroxide and superoxide radicals and hydrogen peroxide” (Rahman et
al., 2012). Nitric oxide (NO) is made by the N-methyl-D-aspartate glutamate receptors in the nervous
system. When these receptors are overly activated, this initiates a “calcium influx” making nitric oxide
9
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and other reactive oxygen species (Rahman et al., 2012). Usually in the healthy brain a normal amount
of reactive oxygen species is not harmful, but in fact it is needed. Reactive oxygen species are involved
in cell signaling in small amounts (Calabrese et al., 2007). However, in the diseased aging brain,
reactive oxygen species accumulate and cause protein accumulation and aggregation. In addition to the
increased production of reactive oxygen species, there is a decreased production of antioxidant agents
such as the enzymes “superoxide dismutase, glutathione peroxidase, and glutathione reductase”
(Andersen, 2004) in the brains of persons with neurodegeneration (Benzi & Moretti, 1995).
The ROS and NOS are able to directly cause protein accumulation by destroying chaperone and
proteasomal processes. The function of the molecular chaperone is to find misfolded proteins and help
to fold them properly. The ubiquitin-proteasome-system (UPS) functions to find and degrade proteins
that are misfolded. Without these two processes, misfolded proteins would accumulate, and eventually
aggregate. A number of studies have shown that NO seems to have destructive effects on the
chaperones and UPS proteins (Nakamura & Lipton, 2007). A process called S-nitrosylation occurs on
chaperone proteins and specific UPS proteins known as “protein-disulfide isomerase, glucose-regulated
protein 78, and heat shock proteins” (Taylor et al., 2002) to cause them to become debilitated. This
process adds an “NO group to a cysteine thiol/sulfhydryl to make an S-nitrosothiol” (Rahman et al.,
2012). These proteins no longer work as they are supposed to; either fixing misfolded proteins or
degrading them, therefore causing a protein accumulation.
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If not causing protein aggregation directly, reactive oxygen species accumulate to create
damage elsewhere in the cell to contribute to the cause of neurodegeneration. ROS made in the
mitochondria from oxidative phosphorylation are able to accumulate and damage the mitochondrial
DNA (mtDNA) itself. Once mutated, mtDNA causes more dysfunction in oxidative phosphorylation
and the mitochondrial structure, leading to a larger accumulation of ROS. It is known as the vicious
cycle of the mitochondria, and once it starts, it does not stop. Antioxidant functions are impaired at this
point in a neurodegenerating cell body so there is no defense against this cycle as it takes over the brain
(Fukui & Moraes, 2008). Damage to the mitochondria will cause a depletion of ATP, an influx in
calcium, and in most cases the opening of the mitochondrial permeability transition pore leading to
apoptosis. Figure 3 below illustrates the viscous cycle of the mitochondria, and what it does to the

neuron.
Figure 3- (Schue A.)
Reactive oxygen species not only cause direct protein accumulation and mitochondrial
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dysfunction, but can also cause glial cell activation and inflammation. (Salminen et al., 2012) When
glial cells detect damage induced by reactive oxygen species, the microglia are stimulated to activate
genes that are involved in the release of cytokines, NO, and NADPH oxidase (Andersen 2004;
Lobsiger & Cleveland, 2007). The cytokines include proinflammatory interleukins-1, and -6, and tumor
necrosis factor-α (TNF-α). These things, in turn, cause damage to the neurons by over-inflammation,
tissue damage, and the production of more reactive oxygen species. NO has detrimental effects on the
cell and once NO is mixed with the superoxide anion reactive oxygen species, peroxynitrite (ONOO-)
is formed which can nitrosylate proteins causing them to become deformed and accumulated. (Zhang et
al., 2012). This form of reactive nitrogen species is thought to be a major part of the β-amyloid protein
toxicity in Alzheimer's disease (Andersen, 2004; Qin et al., 2002).
Certain glial cells known as astrocytes have a specific function in neurodegeneration as well.
Astrocytes are the cells responsible for glutamate, an excitatory factor of the central nervous system.
Over activation of the astrocytes causes altered glutamate handling, leading to abnormal excitatory
processes and calcium signaling waves. (Lobsiger & Cleveland, 2007; Malta et al., 2012). Increased
activation of astrocytes leads to increased chances of death of dopaminergic neurons as seen in the
pathogenesis of Parkinson's disease (Andersen, 2004).
The reactive oxygen species created throughout many processes in neurodegeneration have
deleterious effects on the central nervous system. The ROS are an initiating factor in the process of
apoptosis. These molecules can cause direct damage to open the mitochondrial permeability transition
pore which activates transduction pathways, kinases and releasing cytochrome c. ROS can also have
damaging effects on things like RNA and DNA. The damage done to RNA and DNA can then force a
cell into programmed cell death. Reactive oxygen species activate astrocytes to cause glutamate
excitotoxicity. With this comes a cascade of events causing programmed cell death through the
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activation of NMDA receptors. This causes an influx of calcium, production of nitric oxide (NO), and
depolarization of the mitochondrial membrane. This then causes the mitochondria to produce more
ROS to create more damage, especially to the DNA. An enzyme named poly-ADP-ribose polymerase-1
then comes in to help relocate the damaged DNA. If the enzyme is not present as in many cases of
neurodegeneration, a translocation to the nucleus cannot occur, therefore the death caspases are
activated, causing apoptosis to be initiated. (Krantic et al., 2005). This is an especially dominant
process in motor neurons in the cortex, brain stem, and spinal cord in Amyotrophic Lateral Sclerosis
and in the substantia nigra in Parkinson's disease.
Reactive oxygen species cause damage to the mitochondria, which is in the most part, where
they are produced. They cause damage to the mtDNA itself to produce a vicious cycle of the
mitochondria that is never ending. When ROS start to accumulate, they activate the glial cells, more
specifically, the microglia and astrocytes, to cause neuroinflammation and glutamate excitotoxicity.
Reactive oxygen species can also cause damage to RNA and DNA of the cells, to cause apoptosis.
These molecules with unpaired electrons have detrimental effects on the brain, the neurons, and the
central nervous system as a whole, and can not only initiate neurodegeneration, but can also progress it.
(Ramalingam & Kim, 2012)
Metabolic Derangements and Neurodegenerative Disease
A recent interest in neurodegeneration has been faulty insulin signaling and decreased glucose
metabolism in the brain (Frisardi et al., 2010). Research has found a decline in the brain's ability to
metabolize glucose, known as hypometabolism, with neurodegeneration. We know that this impaired
glucose metabolism is in accordance with the damaged mitochondria. This happens because many of
the key metabolic enzymes are impaired, causing metabolism to be altered. Another factor in the
efficiency of glucose metabolism is insulin signaling. In neurodegeneration there is a defect in insulin
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signaling. Sensitivity to insulin is not only important for the maintenance of glucose metabolism, but it
is also important for learning and memory skills, and in some cases synapse plasticity (Gasparini et al.,
2002). Resistance to insulin causes a deficient metabolism of glucose, which results in less ATP made
for the cell (Rasgon & Jarvik, 2004). It also has been proven to be linked to cognitive function, and
dementia. Impaired glucose metabolism causes problems with acetylcholine formation and disrupts
synaptic transmission causing cognitive dysfunction. One hypothesized way the brain becomes insulin
resistant is by the activity of the IR-tyrosine kinase being decreased, bringing about an error in insulin
signal transduction (Gasparini et al., 2002). It also becomes resistant to insulin through reactive oxygen
species damage (Son et al., 2011). This is the main connection between neurodegeneration and
Diabetes Mellitus (diabetes type II).
Insulin has been found to govern the metabolism of two of the main proteins that accumulate in
Alzheimer's disease. These proteins are known as the beta amyloid protein and the tau protein. Tau is a
protein that usually binds to microtubules and initiates tubulin polymerization (Frisardi et al., 2011).
The tau protein is regulated by phosphorylation through kinases. Consequently, these kinases are downregulated by insulin and insulin growth factor-1 (IGF-1). Therefore, experimental data has shown that
an increase in insulin and IGF-1 comes with a decrease in tau phosphorylation and activation. This
means that the tau protein will function normally. However, if the brain is insulin resistant, these
processes cannot occur and the tau protein is phosphorylated to cause over-activation. Insulin also
regulates the metabolism of the beta amyloid protein in the brain.
Insulin has been shown to help with the clearance of the beta-amyloid precursor protein. With a
decrease in insulin sensitivity, comes an increase in the beta-amyloid precursor protein. There is a wide
variety of hypotheses on how this works and it is still not clear how this happens (Gasparini et al.,
2002). The figure below (Figure 4) shows how insulin resistance initiates protein accumulation in
14
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Alzheimer's disease with other factors, leading to neuron death.
Figure 4- (Son et al., 2011).
Other Diseases Related to Neurodegenerative Diseases
Like many other diseases, neurodegenerative diseases have other diseases that are closely linked
in their etiology and pathogenesis. The first disorder that has a significant relationship with
neurodegenerative diseases is Down's syndrome or Trisomy 21 (Kim et al., 2000; Holtzman et al.,
1996). There is compelling evidence that people with Down's syndrome have a greater chance of
getting Alzheimer's disease, Parkinson's disease, or Huntington's disease. The brain of a person with
Down's syndrome has abnormal neurons, with an accumulation of reactive oxygen species in them.
This causes apoptosis, inflammation, and all of the damaging effects of reactive oxygen species in the
neurons of a person with Down's syndrome. These reactive oxygen species are partly the cause of the
decrease in cognition seen in Down's syndrome, and this is one way this disease predisposes a person
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to Alzheimer's disease and other neurodegeneration (Busciglio & Yankner, 1995).
There is also a compound called dual-speciﬁcity tyrosine-(Y)-phosphorylation regulated kinase
1A (Dyrk1A) that is over-expressed in Down's syndrome brains. Dyrk1A phosphorylates part of the
beta amyloid precursor protein, which increases production of the amyloid precursor protein itself.
Dyrk1A also helps to phosphorylate tau proteins in Down syndrome brains. Both of these processes
help to create abnormal accumulation of these proteins, leading to the pathogenesis of Alzheimer's
disease. The plaques that are observed in geriatric Alzheimer's patients are observed in middle aged
people with Down's syndrome (McQuillan et al., 2003). Dyrk1A is also related to causing accumulation
of other proteins related to other neurodegenerative diseases, including α-synuclein and huntingtininteracting protein. This increases the likeliness of a person with Down's syndrome to acquire
Parkinson’s disease or Huntington’s disease (Park et al., 2009). Many people with Down's syndrome
start showing symptoms of Alzheimer's disease and other dementia by middle age (Park et al., 2009;
Holtzman et al., 1996).
Another disease strongly associated with neurodegeneration, specifically Alzheimer's disease, is
Diabetes Mellitus or diabetes II (Colca & Feinstein, 2012; Beeri et al., 2005). Diabetes Mellitus is
characterized by the resistance to insulin in the body, causing metabolism problems, and in many cases
obesity (Vellas & Sinclair, 2004). Diabetes Mellitus has recently been shown to cause problems with
the central nervous system and cognitive functions, resulting in dementia and neurodegeneration
(Gasparini et al., 2002). Diabetes II is the cause of insulin resistance and has been seen to progress
protein accumulation in Alzheimer's disease (Michal et al., 2005). Insulin, when normally metabolized
in the brain, helps to clear the amyloid beta precursor protein, and helps to down regulate the
phosphorylation of the tau protein (Son et al., 2011). Both of these processes are helpful in avoiding the
initiation and progression of Alzheimer's disease. However in Diabetes Mellitus, insulin resistance is
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increased, and these processes do not occur in the brain, increasing the chances of a person with
Diabetes type II to get Alzheimer's disease. (Korf et al., 2006)
Neurodegeneration has been specifically linked to both Down's syndrome and Diabetes
Mellitus. There have been many hypotheses about how these diseases are connected, and it is still being
researched today. Although no breakthrough cures have been found to counteract the trisomy driven
changes seen in Down's syndrome, many compounds have been found to help with Diabetes Mellitus.
Therefore, the compounds used to help treat Diabetes Mellitus have also been studied for their effects
on neurodegeneration, especially on Alzheimer's disease.
Treatment of Neurodegeneration
There have been many proposed mechanisms as to how to slow down, or even stop the process
of neurodegeneration. Some have been experimented with, and have been proven ineffective. Others
have been effective to stop the symptoms, but not the progression of the disease, and even more are still
being studied.
Insulin resistance plays a big part in neurodegeneration, especially in Alzheimer's disease with
the formation of plaques. Many researchers have found that compounds which sensitize to insulin can
help slow neurodegeneration. These compounds are also used in the treatment of Diabetes Mellitus, as
insulin resistance is the main component in this disorder. Thiazolidinediones (TZDs) used to be the
most common form of insulin sensitizers. Two of these compounds are rosiglitazone and pioglitazone.
These compounds “act as agonists of nuclear receptor peroxisome proliferator-activated receptorgamma (PPAR-γ)” (Son et al., 2011) to directly active the PPAR-γ (Berger & Moller, 2002). This helps
to sensitize the brain to insulin to stop the progression of neurodegeneration and protein accumulation,
and to also decrease neuroinflammation. There are also insulin sensitizing hormones such as ghrelin.
Ghrelin has been found to decrease the phosphorylation of the tau protein, by sensitizing the brain to
17
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insulin. Many types of these compounds are still being researched; however some are being used now
to decrease the progression of Alzheimer's disease and neurodegeneration as a whole. (Son et al., 2011).
Unfortunately, compounds like rosiglitazone and pioglitazone have been found to have adverse side
effects, and this is why studies are still being done to replace them with alternative compounds. (Colca
et al., 2013).
There is also another class of insulin sensitizing compounds to help with the treatment of
neurodegeneration, however these are aimed at a different process in the cell. Since TZDs have been
shown to have damaging effects on the body by directly activating the PPAR-γ, research has been done
to find a different way to sensitize the brain and the body to insulin. New TZDs, known as
mitochondrial target of thiazolidinediones (mTOTs), with a target protein located on the inner
membrane of the mitochondria have become popular, as they work in a way to “change nutrient sensing
pathways and modify Wnt signaling” (Colca & Feinstein, 2012). A change in nutrient sensing pathways
includes an activation of AMPK, a decrease in mTOR activity, and a decrease in inflammatory kinase
activation all which leads to increased insulin activity (Colca et al., 2013). An mTOT compound that is
currently being tested for the use on Alzheimer's patients is called MSDC-0160, which should, in
addition to sensitizing the brain to insulin, stabilize glucose metabolism as well. (Colca & Feinstein,
2012).
Mitochondrial dysfunction is a major part of neurodegeneration. Therefore the mitochondria
have a large role in finding therapeutic means of treating neurodegeneration. The mitochondria serve as
a good target for insulin sensitizers and can be a target for other specific types of therapies as well
(Reddy & Reddy, 2011). It is known that disease specific proteins and compounds relating to
Alzheimer's disease, Parkinson's disease, Huntington's disease, and ALS accumulate and associate with
the mitochondria, including amyloid β protein, α-synuclein protein, parkin, presenelin, huntingtin, and
18
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SOD1. Studies are starting to be done to use this information along with the mitochondria as a
therapeutic target to make a compound to treat neurodegeneration. For a specific example, reducing
amounts of p53 in the mitochondria protects against the mutant huntingtin protein, treating
Huntington's disease. This is just one out of many cases where the mitochondria were used as the
specific target for treatment of neurodegeneration (Lin & Beal, 2006). Another way the mitochondria
are targeted for treatment is through artificially increasing the amounts of ATP in the mitochondria,
which would not only help to increase cellular processes like autophagy, but also “increase synaptic
outgrowth and neuronal connectivity.” (Reddy et al., 2011).
Another large branch of targets for treatments of neurodegeneration is the reactive oxygen
species. A brain with neurodegeneration has an accumulation of reactive oxygen species, with less
antioxidant to defend itself from the harm of ROS. If less reactive oxygen species were found in the
brain, there would be less damage to not only the mitochondria, but to the neurons all together. This is
why antioxidants have been proposed to be a therapeutic mechanism for neurodegeneration.
Mitochondrial targeted antioxidants termed triphenylphosphonium-based antioxidants have been
created, because this is where the majority of reactive oxygen species are formed. These are still in
research, but they seem to be more effective than just simple vitamin C and E (Reddy et al., 2011),
because they are able to cross the blood brain barrier and enter the mitochondria in the neurons. There
have also been findings that certain foods and drinks may have antioxidant effects on the brain as well.
These include curry spice, fruits, vegetables, and green tea (Calabrese et al., 2006; Mandel et al., 2008).
Curry spice contains an antioxidant called curcumin, where fruits and vegetables contain ferulic acid.
Both of these antioxidants were seen to have positive effects on the brain. Green tea contains a
component called epigallocatechin-3-gallate that has been found to protect the brain from ROS and
neuroinflammation (Mandel et al., 2008). Finally the compound melatonin has proven to be a powerful
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antioxidant against ROS and NO. Melatonin protects mitochondrial DNA from damage by the reactive
oxygen species, and allows oxidative phosphorylation to continue undamaged, helping to maintain a
good number of ATP (Cardinali et al., 2013).
There are a number of ways researchers have begun to try to treat neurodegeneration. From
sensitizing the brain to insulin, to targeting the mitochondria directly, to increasing the defense against
reactive oxygen species, numerous aspects surrounding neurodegeneration have been studied. Various
compounds are now in trial, and the outlook is positive, however nothing at this point is surely a cure
of neurodegeneration. Neurodegenerative diseases are very complicated and as suspected; the cure will
be as well.
Conclusion
The incidence of neurodegenerative diseases is rising every year as the elderly population
grows. The devastation that occurs from neurodegeneration is due to many different processes
happening in the central nervous system. Although each neurodegenerative disease has different
profiles of protein accumulation and aggregation, these diseases are thought to have many similarities
in pathogenesis.
Mitochondrial dysfunction plays a significant role in the neurodegeneration of the brain.
Mitochondrial dysfunction occurs from mtDNA mutations, reactive oxygen species, loss of calcium
homeostasis, and protein accumulation in the mitochondria itself. Once reactive oxygen species form,
they can cause detrimental effects to our neurons like neuroinflammation, apoptosis, damage to
proteasomal function, and damage to DNA and mtDNA. Derangement of the metabolism of reactive
oxygen species, protein, and glucose all cause problems in the brain. With a defect in glucose
metabolism comes problems in insulin signaling and insulin sensitivity, which brings about specific
pathology relating to Alzheimer's disease. Many of these problems have specific relationships to certain
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disorders, especially to Down's syndrome and to Diabetes Mellitus.
To treat neurodegenerative diseases, the mitochondria have become a prime target. In many
models pathology initiates in the mitochondria, making it a good place to start for therapeutics to cure
neurodegeneration. Insulin sensitization is another way that treatment of neurodegeneration could be
achieved, as it could restore glucose metabolism and ATP production. Finally antioxidants play a role in
the treatment of neurodegeneration, since ROS accumulation is a big part in the neurodegeneration of a
human. Neurodegeneration is a very complicated disease, and it will take a lot of time and research to
come up with specific treatments to prevent it from occurring.
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